MYGN - Myriad Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
25.76
+0.56 (+2.22%)
At close: 4:00PM EDT

25.76 0.00 (0.00%)
After hours: 5:00PM EDT

Stock chart is not supported by your current browser
Previous Close25.20
Open25.50
Bid25.74 x 900
Ask25.71 x 1800
Day's Range24.97 - 25.89
52 Week Range24.97 - 50.44
Volume1,052,883
Avg. Volume879,803
Market Cap1.89B
Beta (3Y Monthly)1.08
PE Ratio (TTM)91.67
EPS (TTM)0.28
Earnings DateAug 19, 2019 - Aug 23, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.42
Trade prices are not sourced from all markets
  • Why Should You Hold on to Myriad Genetics (MYGN) Stock?
    Zacks13 hours ago

    Why Should You Hold on to Myriad Genetics (MYGN) Stock?

    Investor confidence is still high on growth prospects of Myriad Genetics (MYGN).

  • Myriad Genetics Reduced 2019 Guidance, but Is It Really So Bad?
    Motley Fool7 days ago

    Myriad Genetics Reduced 2019 Guidance, but Is It Really So Bad?

    The genetic testing pioneer lost $500 million in value after reporting fiscal Q3 operating results.

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Myriad Genetics Inc.

    Myriad Genetics Inc NASDAQ/NGS:MYGNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining Bearish sentimentShort interest | NeutralShort interest is moderately high for MYGN with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on May 9. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding MYGN are favorable, with net inflows of $2.94 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire8 days ago

    Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting

    SALT LAKE CITY, May 14, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will present results from multiple studies at.

  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of MYGN earnings conference call or presentation 7-May-19 8:30pm GMT

    Q3 2019 Myriad Genetics Inc Earnings Call

  • GlobeNewswire13 days ago

    New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy

    Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, today announced that the EndoPredict® test (EPclin) identifies women with early-stage breast cancer who can safely forgo extended endocrine therapy five years after diagnosis.  Findings from the study were published in the journal Clinical Cancer Research.

  • Why Marathon Petroleum, Livent, and Myriad Genetics Slumped Today
    Motley Fool13 days ago

    Why Marathon Petroleum, Livent, and Myriad Genetics Slumped Today

    These stocks struggled on a mixed day on Wall Street.

  • Myriad Genetics Inc (MYGN) Q3 2019 Earnings Call Transcript
    Motley Fool13 days ago

    Myriad Genetics Inc (MYGN) Q3 2019 Earnings Call Transcript

    MYGN earnings call for the period ending March 31, 2019.

  • Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up
    Zacks14 days ago

    Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up

    Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.

  • Myriad Genetics (MYGN) Beats Q3 Earnings Estimates
    Zacks14 days ago

    Myriad Genetics (MYGN) Beats Q3 Earnings Estimates

    Myriad (MYGN) delivered earnings and revenue surprises of 4.55% and -0.81%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press14 days ago

    Myriad: Fiscal 3Q Earnings Snapshot

    On a per-share basis, the Salt Lake City-based company said it had profit of 9 cents. Earnings, adjusted for one-time gains and costs, came to 46 cents per share. The results topped Wall Street expectations. ...

  • GlobeNewswire14 days ago

    Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results

    Total Third-Quarter Revenues of $216.6 Million, Up 18 PercentThird-Quarter Diluted EPS of $0.09 and Adjusted EPS of $0.46, Up 35 Percent SALT LAKE CITY, May 07, 2019 -- Myriad.

  • GlobeNewswire20 days ago

    Myriad Announces Coverage Decision by Kroger® Prescription Plans for GeneSight®

    SALT LAKE CITY, May 01, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a worldwide leader in personalized medicine, today announced that Kroger Prescription Plans, will provide.

  • GlobeNewswire21 days ago

    Myriad Genetics to Present at Two Upcoming Healthcare Conferences

    SALT LAKE CITY, May 01, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at two.

  • GlobeNewswire21 days ago

    EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer

    Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, today announced an international team of cancer researchers has found that EndoPredict® test accurately predicts which women with ER-positive, HER2-negative breast cancer will benefit from adjuvant chemotherapy.  Findings from the study were published today in the journal Breast Cancer Research and Treatment. This study evaluated the ability of the EndoPredict test (EPclin) to predict chemotherapy benefit based on the analysis of the 10-year distant recurrence rate (i.e., metastasized cancer) in women with ER-positive, HER2-negative breast cancer who received five years of endocrine therapy (ET) alone or in combination with chemotherapy (ET+C).  Data from 3,746 women (2,630 on ET alone and 1,116 on ET+C) were included in the analysis.  The study found that women with a high EndoPredict score (i.e., 3.3) and who received ET+C had significantly lower 10-year recurrence risk than those on ET alone (Graph 1).  However, there were no significant differences between ET+C and ET for patients with low EndoPredict scores, suggesting these women are unlikely to benefit from adjuvant chemotherapy.

  • Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?
    Zacks21 days ago

    Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?

    Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Here’s What Hedge Funds Think About Myriad Genetics, Inc. (MYGN)
    Insider Monkey22 days ago

    Here’s What Hedge Funds Think About Myriad Genetics, Inc. (MYGN)

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]

  • GlobeNewswire28 days ago

    Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019

    SALT LAKE CITY, April 23, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal third-quarter 2019 sales.

  • 3 Medical Product Stocks Set to Beat This Earnings Season
    Zacks28 days ago

    3 Medical Product Stocks Set to Beat This Earnings Season

    The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.

  • GlobeNewswire29 days ago

    Myriad to Present Multiple Women’s Health Studies at the 2019 American College of Obstetricians and Gynecologists Annual Meeting

    “We are focused on improving the lives of women with our pioneering science and are looking forward to presenting several exciting studies at ACOG this year,” said James Goldberg, M.D., board certified maternal fetal medicine specialist, medical geneticist and chief medical officer, Myriad Women’s Health. Please visit Myriad Women’s Health at booth #1041 to learn more about our leading portfolio of women’s health products.

  • Top Gene-Sequencing Stocks for 2019
    Motley Foollast month

    Top Gene-Sequencing Stocks for 2019

    These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

  • Why Myriad Genetics, Inc. (NASDAQ:MYGN) Is A Financially Healthy Company
    Simply Wall St.last month

    Why Myriad Genetics, Inc. (NASDAQ:MYGN) Is A Financially Healthy Company

    Mid-caps stocks, like Myriad Genetics, Inc. (NASDAQ:MYGN) with a market capitalization of US$2.4b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. Despite this...

  • GlobeNewswirelast month

    Myriad Genetics Named to Forbes 2019 List of America's Best Midsize Employers and the Women Tech Council’s 2019 Shatter List

    Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, today announced today announced that the company was named to Forbes 2019 list of America's Best Midsize Employers for the third year in a row. “We are excited to again be recognized by both Forbes and the Women’s Tech Council for creating a company culture that empowers our employees to grow and become the best versions of themselves,” said Mark C. Capone, president and CEO, Myriad Genetics.